21st Century Cures Act: Regenerative Medicine Initiative - Research Projects

Active

Assistance listing
93.CRP
Agency
Grant awards
Not on record

Program facts

Also known as
Regenerative Medicine Initiative
Treasury account
  • 75-5628-0-2-552
More information

Program details come from SAM.gov Assistance Listings. Updated .

About this program

The National Institutes of Health under the Department of Health and Human Services funds clinical research on adult stem cells and regenerative medicine therapies through the Regenerative Medicine Innovation Project, established under the 21st Century Cures Act (CFDA 93.CRP), with grant and cooperative agreement awards made annually based on competitive peer review.

The program supports clinical research projects that advance the field of regenerative medicine using adult stem cells, conducted in close collaboration with the U.S. Food and Drug Administration to ensure scientific rigor and patient safety. The NIH RMIP is one of four Innovation Projects authorized under the Cures Act; the others are the Precision Medicine Initiative ("All of Us"), the Beau Biden Cancer Moonshot, and the BRAIN Initiative. Grants and cooperative agreements are awarded on a competitive basis, with awards typically structured for initial project periods of 3 to 5 years, with a maximum of 5 years; renewals may be awarded for additional periods of up to 5 years subject to competitive peer review. The source does not report recent grant awards, award frequency trends, or the dollar magnitude of individual awards. The 21st Century Cures Act originally authorized $30 million over four years for the program; current funding levels and annual award volume are not specified in the source.

Eligible applicants include universities, colleges, hospitals, public agencies, nonprofit research institutions, and for-profit organizations. Grant applications must be approved for scientific and merit review by a scientific review group and a national advisory council before funding. The source does not identify any currently open grant opportunities or their application deadlines. Financial records must be retained for three years from the submission of the final expenditure report for the grant period.

Objective and description

Objective

The Regenerative Medicine Innovation Project (RMIP) was established by the 21st Century Cures Act to accelerate progress in the field by supporting clinical research on adult stem cells, while promoting scientific rigor and protecting patient safety

Description

The RMIP is one of four Innovation Projects authorized under the Cures Act; the others are the Precision Medicine Initiative ("All of Us"), the Beau Biden Cancer Moonshot, and the BRAIN Initiative. The NIH RMIP launched following passage of the 21st Century Cures Act, which authorized $30 million over four years "for clinical research to further the field of regenerative medicine using adult stem cells." NIH continues to work in close collaboration with the U.S. Food and Drug Administration to implement the RMIP.

Eligibility

Applicant eligibility

The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that applies and receives a grant for support of research by a named principal investigator. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary eligibility

Grants and Cooperative Agreements: Average 3 to 5 years, and a maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Method of awarding/releasing assistance: letter

Uses of assistance

Grants and cooperative agreements may be made to eligible institutions for the support of the BRAIN Initiative. The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and Facilities and Administrative Costs (formerly known as indirect costs).

Use restrictions

Grants and cooperative agreements may be made to eligible institutions for the support of the BRAIN Initiative. The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and Facilities and Administrative Costs (formerly known as indirect costs).

How to apply

Award procedure

Grants and cooperative agreements are funded based on scientific merit, program relevance, and program balance and are made annually. The initial grant award provides funds for the first budget period (usually 12 months) and letter Notice of Award indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories and special conditions, if any.

Time to approval or disapproval

approximately 10 months

Renewals

Applications submitted for renewal are reviewed and selected for funding on a competitive basis.

Appeals

A principal investigator may question the substantive or procedural aspects of the review of his/her application by communicating with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page www.nih.gov/grants/guide/notice-files/not97-232.html .

Quick answers

What is Assistance Listing 93.CRP?

Assistance Listing 93.CRP is 21st Century Cures Act: Regenerative Medicine Initiative - Research Projects, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for 21st Century Cures Act: Regenerative Medicine Initiative - Research Projects?

Its CFDA number is 93.CRP: Assistance Listing numbers were called CFDA numbers before 2018.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program